TPTX - Turning Point Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
50.00
+4.08 (+8.89%)
As of 2:37PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close45.92
Open45.66
Bid49.20 x 800
Ask49.80 x 1300
Day's Range45.66 - 50.40
52 Week Range24.21 - 50.40
Volume111,307
Avg. Volume170,619
Market Cap1.56B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.20
Trade prices are not sourced from all markets
  • GlobeNewswire

    Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results

    FDA Accepts Repotrectinib Recommended Phase 2 Dose Regimen for Registrational TRIDENT-1 Study Two Abstracts Selected for Presentation at the European Society for Medical.

  • What Kind Of Shareholder Appears On The Turning Point Therapeutics, Inc.'s (NASDAQ:TPTX) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Turning Point Therapeutics, Inc.'s (NASDAQ:TPTX) Shareholder Register?

    If you want to know who really controls Turning Point Therapeutics, Inc. (NASDAQ:TPTX), then you'll have to look at...

  • GlobeNewswire

    Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the 39th Annual Canaccord Genuity Growth Conference on Aug. 8 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1 clinical study of patients with advanced solid tumors harboring genetic alterations in MET. “We believe the precision therapies we are designing and developing have potential to assist many patients with oncogenic driven cancers, making the start of this new clinical study an important step toward that goal,” said Athena Countouriotis, M.D, chief executive officer of Turning Point Therapeutics.

  • GlobeNewswire

    Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today named Yi Larson as executive vice president and chief financial officer, effective Aug. 26. Ms. Larson joins the company from Goldman Sachs & Co. where she worked for more than 12 years and most recently served as managing director of Healthcare Investment Banking. “Yi brings an important new dimension to our growing team from her experience advising biotechnology companies through more than $100 billion in financing and strategic transactions,” said Athena Countouriotis, M.D, president and chief executive officer.

  • GlobeNewswire

    Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Carol Gallagher, Pharm.D. to its board of directors. Dr. Gallagher brings nearly 30 years of biotech leadership, board and investing experience, currently serving as a partner for New Enterprise Associates (NEA). “Carol has nurtured the growth of many biotechnology companies during her distinguished career as both an operating executive and board member,” said Dr. Sheila Gujrathi, chair of the Turning Point Therapeutics board.

  • GlobeNewswire

    Turning Point Therapeutics to Host Second Quarter 2019 Conference Call

    SAN DIEGO, July 22, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report.

  • GlobeNewswire

    Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of the registrational Phase 2 portion of its TRIDENT-1 clinical study of patients with ROS1+ advanced non-small cell lung cancer and TRK+ advanced solid tumors. Patients will be treated with Turning Point’s lead investigational kinase inhibitor, repotrectinib, which has been studied in more than 80 patients in the ongoing Phase 1 portion of the study.

  • Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
    MarketWatch

    Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

    Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.

  • GlobeNewswire

    Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the Goldman Sachs 40th Annual Global Healthcare Conference on June 11 in Rancho Palos Verdes, Calif. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer

    In TKI-naïve ROS1+ Patients, Overall Response Rate by Blinded Review is 82 Percent, and 83 Percent at Likely Recommended Phase 2 Dose of 160 mg QD or Above; Median Duration of.

  • American City Business Journals

    Bay Area figures prominently in hottest IPOs so far this year

    All six have doubled in value — or more — since their Wall Street debuts and they are either headquartered in the Bay Area or backed by investors from the region.

  • GlobeNewswire

    Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor

    The study is designed to assess the safety, tolerability, and preliminary clinical activity of TPX-0022 at escalating doses in patients with advanced or metastatic solid tumors harboring genetic alterations in MET. TPX-0022 has been designed to target MET-driven tumor cells, and also modulate the tumor microenvironment by inhibition of CSF1R. “The clearance of our IND for TPX-0022 is another important milestone toward our goal to bring a new class of precision therapies to patients,” said Athena Countouriotis, M.D., president and chief executive officer.

  • GlobeNewswire

    Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs that address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a question and answer session at the UBS Global Healthcare Conference on May 21 in New York. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Patrick Machado, J.D. to its board of directors. Mr. Machado brings more than 20 years of biotech management and board experience, including as co-founder and chief business and financial officer of Medivation, Inc. “Pat has built a strong reputation in the biotech and broader business community for the tremendous value he has added at multiple companies throughout his career,” said Athena Countouriotis, M.D, president and chief executive officer.

  • GlobeNewswire

    Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Food and Drug Administration (FDA) of an investigational device exemption (IDE) for the diagnostic assay that will be used in Turning Point’s registrational phase 2 clinical study. The next-generation sequencing (NGS) assay is intended for use in identifying patients with ROS1, NTRK1-3 and ALK gene fusions in advanced solid tumors. Clinical investigators will use the diagnostic test to determine molecular eligibility for enrollment into Turning Point’s registrational Phase 2 portion of the global TRIDENT-1 clinical study.

  • GuruFocus.com

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Brigham Minerals, Turning Point Therapeutics, OPKO Health and ARMOUR Residential

  • GuruFocus.com

    Turning Point Therapeutics Inc (TPTX) President & CEO Athena Countouriotis Bought $216,000 ...

    President & CEO of Turning Point Therapeutics Inc (NASDAQ:TPTX) Athena Countouriotis bought 12,000 shares of TPTX on 04/22/2019 at an average price of $18 a share.

  • GlobeNewswire

    Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    SAN DIEGO, April 22, 2019 -- Turning Point Therapeutics, Inc. (Nasdaq:TPTX), a clinical-stage precision oncology company designing and developing novel drugs to address.

  • Benzinga

    Turning Point Therapeutics IPO: What You Need To Know

    When Turning Point Therapeutics hits the markets Wednesday, it wants to pivot your portfolio toward the rich field of oncology. The IPO Turning Point has priced 9.25 million shares at $18 per share on ...

  • Business Wire

    Turning Point Therapeutics Announces Pricing of Initial Public Offering

    Turning Point Therapeutics, Inc. (TPTX), a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, today announced the pricing of its initial public offering of 9,250,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Turning Point Therapeutics from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $166.5 million. The shares are expected to begin trading on the Nasdaq Global Market on April 17, 2019 under the symbol "TPTX".

  • Benzinga

    IPO Outlook For The Week: Pinterest, Zoom, Biotechs, Minerals And Catastrophe Insurance

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Brainsway Ltd (BWAY) will issue 2.5 million shares at $11.94 Wednesday ...